BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33495420)

  • 21. MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells.
    Chai C; Wu H; Wang B; Eisenstat DD; Leng RP
    Carcinogenesis; 2018 Sep; 39(9):1185-1196. PubMed ID: 29985991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of circular RNA hsa_circ_0001649 indicates poor prognosis for retinoblastoma and regulates cell proliferation and apoptosis via AKT/mTOR signaling pathway.
    Xing L; Zhang L; Feng Y; Cui Z; Ding L
    Biomed Pharmacother; 2018 Sep; 105():326-333. PubMed ID: 29864621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circular RNA hsa_circ_0072995 promotes breast cancer cell migration and invasion through sponge for miR-30c-2-3p.
    Zhang HD; Jiang LH; Hou JC; Zhou SY; Zhong SL; Zhu LP; Wang DD; Yang SJ; He YJ; Mao CF; Yang Y; Wang JY; Zhang Q; Xu HZ; Yu DD; Zhao JH; Tang JH; Ji ZL
    Epigenomics; 2018 Sep; 10(9):1229-1242. PubMed ID: 30182731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620.
    Li X; Shen M
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(2):555-566. PubMed ID: 30720163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells.
    Zhang Y; Zhao Z; Li S; Dong L; Li Y; Mao Y; Liang Y; Tao Y; Ma J
    Mol Med Rep; 2019 May; 19(5):4035-4042. PubMed ID: 30942417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
    Teng P; Jiao Y; Hao M; Tang X
    J Cell Biochem; 2018 Jul; 119(7):5243-5252. PubMed ID: 29236322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression.
    Chen D; Ma W; Ke Z; Xie F
    Cell Cycle; 2018; 17(16):2080-2090. PubMed ID: 30176158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
    Zhang S; Wang M; Li Q; Zhu P
    Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
    Deng M; Wang J; Chen Y; Zhang L; Liu D
    Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
    Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
    J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047.
    Guo J; Chen M; Ai G; Mao W; Li H; Zhou J
    Biomed Pharmacother; 2019 Jul; 115():108957. PubMed ID: 31082770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circular RNA hsa-circ-0012129 Promotes Cell Proliferation and Invasion in 30 Cases of Human Glioma and Human Glioma Cell Lines U373, A172, and SHG44, by Targeting MicroRNA-661 (miR-661).
    Xie G
    Med Sci Monit; 2018 Apr; 24():2497-2507. PubMed ID: 29686222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression.
    Zou Y; Zheng S; Xiao W; Xie X; Yang A; Gao G; Xiong Z; Xue Z; Tang H; Xie X
    Carcinogenesis; 2019 Dec; 40(12):1469-1479. PubMed ID: 31001629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.
    Liu L; Yu D; Shi H; Li J; Meng L
    Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
    Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.